Asthma is a chronic inflammatory airway disease characterized by bronchial hyperresponsiveness, airflow obstruction, and respiratory symptoms including wheezing, dyspnea, and cough. Pharmacological management aims to control symptoms, reduce exacerbations, and maintain normal lung function through a stepwise approach.
What Is Asthma Pharmacotherapy?
Asthma drugs are classified into relievers (used as needed for acute symptom relief) and controllers (taken regularly to achieve and maintain disease control). The Global Initiative for Asthma (GINA) guidelines recommend an anti-inflammatory-based stepwise approach, with inhaled corticosteroids (ICS) as foundational therapy for most patients. Treatment is adjusted up or down based on symptom control and exacerbation risk.
Drug Classes and Mechanisms
Short-acting beta-agonists (SABAs) such as albuterol act as bronchodilators by stimulating beta-2 adrenergic receptors in airway smooth muscle, causing rapid relaxation. They are first-line reliever therapy but should not be used as monotherapy for persistent asthma.
Inhaled corticosteroids (ICS) including fluticasone, budesonide, beclomethasone, and mometasone suppress airway inflammation by reducing inflammatory cytokine production, eosinophil activity, and airway hyperresponsiveness. They are the cornerstone of controller therapy.
Long-acting beta-agonists (LABAs) such as salmeterol and formoterol provide sustained bronchodilation for twelve hours or more. LABAs are always used in combination with ICS, never as monotherapy, due to increased mortality risk observed with LABA monotherapy in early trials.
Leukotriene receptor antagonists (LTRAs) including montelukast block cysteinyl leukotriene receptors, reducing bronchoconstriction, mucus secretion, and eosinophilic inflammation. They are oral agents useful as add-on therapy, particularly in exercise-induced asthma and aspirin-sensitive asthma.
Theophylline is a methylxanthine bronchodilator with mild anti-inflammatory effects. Its narrow therapeutic window and significant drug interactions limit its use to third-line add-on therapy.
Biologics represent targeted therapies for severe asthma. Omalizumab (anti-IgE) is indicated in allergic asthma with elevated IgE. Mepolizumab and benralizumab target IL-5 and the IL-5 receptor respectively, reducing eosinophilic inflammation in severe eosinophilic asthma. These agents are reserved for patients with poorly controlled disease despite maximal inhaled therapy.
Therapeutic Uses
The stepwise GINA approach begins with as-needed low-dose ICS-formoterol for symptom relief in mild asthma. Step 2 adds regular low-dose ICS. Step 3 introduces low-dose ICS-LABA as maintenance. Step 4 increases to medium-dose ICS-LABA. Step 5 includes high-dose ICS-LABA plus add-on therapies such as tiotropium, LTRAs, or biologics. Treatment is personalized based on symptom control, exacerbation history, phenotype, and patient preference.
Adverse Effects
SABAs and LABAs may cause tremor, tachycardia, and hypokalemia. ICS are associated with oropharyngeal candidiasis, dysphonia, and at high doses with reduced bone density and adrenal suppression. LTRAs are generally well tolerated but have rare neuropsychiatric effects reported with montelukast. Theophylline toxicity manifests as nausea, vomiting, arrhythmias, and seizures at supratherapeutic levels. Biologics carry risks of injection-site reactions, hypersensitivity, and in rare cases anaphylaxis.
Key Clinical Considerations
Correct inhaler technique is critical for drug delivery and clinical outcomes. Spacer devices improve lung deposition for pressurized metered-dose inhalers. Regular adherence assessment and inhaler technique review should occur at every visit. Combination ICS-LABA inhalers improve adherence by reducing device burden. Smoking reduces ICS efficacy, making smoking cessation essential in asthma management.
Conclusion
Asthma pharmacotherapy requires a stepwise, individualized approach balancing symptom control with exacerbation risk reduction. Inhaled corticosteroids form the therapeutic foundation, with bronchodilators and biologics serving as complementary agents for appropriate patient populations.
